AR and pachyonychia congenita: Approved therapies for castration-resistant PC (CRPC) include agents that target AR signaling (e.g., enzalutamide, abiraterone acetate), chemotherapy (e.g., docetaxel, cabazitaxel), radionuclide therapy (e.g., radium-223, LuPSMA-617), and genomic driven therapies, such as poly(ADP-ribose) polymerase inhibitors for breast cancer gene–mutated PC (2–4).